Merck’s stock climbed by 1.35% in the latest trading session, extending a broader upswing that has seen the share price advance by approximately 41% over the past six months. This gain outpaced the S&P 500’s total return of around 15% over the same period, reflecting growing investor confidence in Merck’s late-stage pipeline and franchise products. Trading volume on the day was 20% above its 30-day average, indicating strong participation from both institutional and retail investors.

While Keytruda remains Merck’s flagship oncology therapy, market participants are increasingly focused on the company’s next-generation assets. Analysts have highlighted two non-oncology molecules, Capvaxive and Winrevair, which are expected to report Phase 2 data in the first half of 2026. Both programs have received Breakthrough Therapy designations in preliminary filings, and consensus estimates suggest peak annual sales of $2 billion combined. Merck has allocated an incremental $300 million to support enrollment in the pivotal studies for these programs, underscoring its commitment to diversifying future revenue streams.

Beyond its immuno-oncology leadership, Merck’s Animal Health division and established non-oncology franchises will be key drivers in the coming quarter. Management has guided for low-double-digit percentage growth in Animal Health revenues, backed by new vaccine introductions in Europe and Asia. Meanwhile, the recently launched Type 2 diabetes asset is projected to contribute an incremental $150 million in Q4 sales, as prescribers adopt the therapy in combination regimens. Investors will be watching Merck’s Q4 report for updates on these businesses, as well as any revisions to full-year guidance based on late-cycle momentum.